Akiko Maehara
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (14)
BACKGROUND: Limited data are available regarding the relative rates, etiology, and long-term prognostic implications of spontaneous myocardial infarction (MI) after percutaneous coronary intervention (PCI) versus coronary artery bypass graft (CABG) surgery for left main coronary artery disease (LMCAD). METHODS: MIs after PCI and CABG for LMCAD were adjudicated from the EXCEL trial (Evaluation of Xience Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization). Cox proportional hazards regression was performed to assess the association between spontaneous (and procedural) MI and cardiovascular and all-cause mortality at 5 years. RESULTS: Among 1882 patients who underwent LMCAD revascularization, spontaneous MI during 5-year follow-up occurred in 60 (6.8%) patients after PCI and in 29 (3.4%) patients after CABG (adjusted hazard ratio [adjHR], 2.01; 95 CI, 1.29–3.15; P =0.002). By multivariable analysis, spontaneous MI (as a time-adjusted covariate) was a strong independent predictor of subsequent cardiovascular mortality (adjHR, 9.39; 95% CI, 5.22–16.87) and all-cause mortality (adjHR, 4.77; 95% CI, 2.92–7.80) within 5 years, with consistent effects after PCI and CABG ( P interaction =0.60 and 0.78, respectively). In the same models, procedural MI as defined by extensive myonecrosis was associated with 5-year cardiovascular (adjHR, 3.02; 95% CI, 1.64–5.56) and all-cause mortality (adjHR, 2.38; 95% CI, 1.48–3.80), with consistent effects after PCI and CABG ( P interaction =0.23 and 0.34, respectively). CONCLUSIONS: In the EXCEL trial, spontaneous MI occurred relatively infrequently within 5 years after LMCAD revascularization but at a higher rate after PCI compared with CABG. Spontaneous MI after revascularization was strongly related to subsequent cardiovascular and all-cause mortality, consistently after PCI and CABG, and was more strongly associated with mortality than was large procedural MI.
Year:
2026
Intravascular ultrasound (IVUS) has been in clinical use for over three decades. Despite evidence that supports the application of the technology from multiple registries, randomised trials and meta-analyses, adoption remains low. Potential barriers to the adoption of IVUS are a lack of understanding as to how to accurately interpret images and how to incorporate it into clinical workflow. To address this, this paper summarises evidence-based protocols for the application of IVUS during percutaneous coronary intervention (PCI) into an easily understood workflow. Standardisation of approaches and wider adoption of IVUS-optimised PCI should improve patient outcomes and PCI durability.
Year:
2026
BACKGROUND: The treatment of calcified coronary lesions requires optimal lesion preparation to achieve a larger minimal stent area (MSA), the strongest predictor of long-term outcomes. The comparative mechanisms of action of calcium-modifying therapies have not been well defined. METHODS: In a prospective, multicenter ECLIPSE trial (Evaluation of Treatment Strategies for Severe Calcific Coronary Arteries: Orbital Atherectomy Versus Conventional Angioplasty Technique Before Implantation of Drug-Eluting Stents), 2005 patients with severely calcified lesions were randomized to vessel preparation with orbital atherectomy (OA) versus balloon angioplasty (BA) before drug-eluting stent implantation. The primary end point of the optical coherence tomography (OCT) substudy was the MSA at the site of maximal calcification; MSA across the entire stent was also assessed. RESULTS: Postprocedural OCT images were available in 286 lesions in 276 patients treated with OA and 292 lesions in 279 patients treated with BA. By angiographic core laboratory analysis, 567 (98.1%) of lesions were severely calcified. By postprocedural OCT, the maximal calcium arc, maximal calcium thickness, and total calcium length measured 204° (149°–268°), 0.85 mm (°0.69–1.03°), and 22.0 (16.0–31.0) mm. Compared with BA, calcium modification was greater in the OA group (greater number, total length, and maximal depth of calcium fractures), especially in lesions with thicker calcium. Nonetheless, the MSA at the site of maximal calcification was large in both groups and not different (median [interquartile range], 7.44 [6.03–8.94] mm 2 versus 7.05 [5.78–8.66] mm 2 ; P =0.08). Similar results were observed for the MSA across the entire stent (5.86 [4.60–7.38] mm 2 versus 5.57 [4.50–6.97] mm 2 ; P =0.10). Among patients in the OCT substudy, 1-year target-vessel failure rates were low and not different between the groups (7.8% with OA and 6.6% with BA, P =0.61). CONCLUSIONS: In lesions that are severely calcified by angiography, the extent of calcification by OCT was highly variable. Despite greater calcium modification after OA, the acute MSA and 1-year target-vessel failure rates were not different between OA and BA. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03108456.
Year:
2026
BACKGROUND: Calcified nodules (CNs) remain a major challenge in percutaneous coronary intervention (PCI). We sought to compare procedural and clinical outcomes after orbital atherectomy (OA) versus intravascular lithotripsy (IVL)-facilitated PCI in patients with CNs. METHODS: We identified patients with optical coherence tomography (OCT)-defined CNs who underwent PCI with either OA or IVL between 2012 and 2022 and had both pre- and post-PCI OCT images available. The imaging end point was the minimal stent area on final post-PCI OCT. The clinical end point was 2-year target-lesion failure, a composite of cardiac death, target-vessel myocardial infarction, or clinically driven target-lesion revascularization. A multivariable Cox proportional hazards regression model was used to estimate hazard ratio and 95% CI. Sensitivity analyses were performed using propensity score matching, incorporating covariates such as age, sex, diabetes, and pre-PCI calcium burden assessed by OCT (length, arc, and thickness). RESULTS: Among 4856 patients with evaluable pre- and post-PCI OCT images, 493 patients (10.2%) had CNs, and 167 patients underwent PCI with either OA (n=83) or IVL (n=84). The 2 groups had similar baseline demographic and lesion characteristics. After PCI, final minimal stent area was comparable between the 2 groups (OA, 5.6 mm 2 [interquartile range, 4.8–6.7] versus IVL, 5.5 mm 2 [interquartile range, 4.8–7.0]; P =0.75). At a median follow-up of 2.4 years, there was no difference in target-lesion failure between the OA and IVL groups (12.0% versus 9.8%, respectively; log-rank P =0.64; adjusted hazard ratio, 1.10 [95% CI, 0.28–4.31]; P =0.89). Overall results remained consistent in the propensity score-matched population (n=68 per group), with similar minimal stent area (5.6 mm 2 [4.8–6.7] versus 5.5 mm 2 [4.7–6.8]; P =0.73) and comparable 2-year target-lesion failure rate (9.8% versus 8.8%; log-rank P =0.82). CONCLUSIONS: In patients with OCT-defined CNs, OA- and IVL-assisted PCI resulted in comparable post-PCI minimal stent area and 2-year clinical outcomes.
Year:
2025
Background The optimal management strategy for in‐stent restenosis (ISR) remains unclear. We aimed to determine the safety and efficacy of percutaneous coronary intervention with XIENCE cobalt chromium everolimus‐eluting stents (EES) for treatment of ISR. Methods In the ILUMIEN IV (Optical Coherence Tomography Guided Coronary Stent Implantation Compared to Angiography: A Multicenter Randomized Trial in Percutaneous Coronary Intervention) trial, the 1‐year outcomes of all randomized patients with a single diffuse or multifocal single‐layer ISR lesion treated with EES were compared with a performance goal. The primary end point was target lesion failure, the composite of cardiac death, target vessel‐myocardial infarction, or ischemia‐driven target lesion revascularization. Outcomes in patients with a single EES‐treated ISR and non‐ISR lesion were also compared. Results From May 2018 through December 2020, 247 patients with a single ISR lesion were treated with EES. Target lesion failure at 1 year occurred in 18 patients (7.4% [upper 1‐sided 97.5% CI, 11.5%]), which was lower than the predefined performance goal of 20% ( P <0.001). Compared with non‐ISR lesions treated with EES (n=2021), the postpercutaneous coronary intervention minimal stent area by optical coherence tomography was smaller in treated ISR lesions (5.0±1.8 mm 2 versus 5.6±1.9 mm 2 ; P <0.001), but minimum stent expansion was similar (78.8±18.0% versus 79.0±16.9%; P =0.87), as was 1‐year target lesion failure (7.4% versus 4.7%; hazard ratio, 1.58 [95% CI, 0.95–2.61]; P =0.07). Conclusions XIENCE EES was safe and effective for treatment of single‐layer ISR. Compared with non‐ISR lesions, ISR lesions treated with EES had a smaller postpercutaneous coronary intervention minimal stent area although stent expansion and 1‐year target lesion failure rates were not different. Registration URL: https://clinicaltrials.gov/ ; Unique identifier: NCT03507777.
Year:
2025
BACKGROUND: Coronary stenting alters vessel dynamics, displacing hinge movement closer to stent edges. We aimed to investigate whether calcified nodules (CNs) are more frequent at stent edges associated with calcium. METHODS: In vessels with previously implanted stents evaluated by optical coherence tomography, 4 different calcified lesions were studied: stent-edge calcified lesions with or without a CN, and unstented native calcified lesions with or without a CN. RESULTS: In 801 patients, 989 stent-edge calcified lesions and 354 unstented native calcified lesions were identified. Stent-edge calcified lesions exhibited a higher prevalence of CNs versus native calcified lesions (15.7% versus 5.1%; P <0.001) and were observed in locations (mid left anterior descending artery, mid left circumflex, or branches) where no unstented native vessel CNs were seen. Stent-edge (versus native vessel) location (odds ratio [OR], 4.58 [95% CI, 2.23–9.43]) predicted the presence of a CN. Correspondingly, greater angiographic (systole-diastole) ∆angle at the stent edge or unstented lesion (per 10°, OR, 2.27 [95% CI, 1.43–3.60]) and greater calcium burden: calcium length (per 10 mm, OR, 4.04 [95% CI, 2.36–6.92]), maximum calcium arc (per 90°, OR, 1.65 [95% CI, 1.25–2.17]), and maximum calcium thickness (per 0.1 mm, OR, 1.25 [95% CI, 1.15–1.36]) were associated with the presence of a CN. Stent-edge CNs were associated with a higher rate of stent-edge calcified lesion-related major adverse cardiac events (a composite of cardiac death, target vessel-related myocardial infarction, clinically driven target lesion revascularization, or definite/probable stent thrombosis) compared with stent edges without a CN (15.9% versus 6.5%; P =0.01), mainly driven by target lesion revascularization. CONCLUSIONS: Stent-edge calcium may predispose to the development of a CN. Stent-edge CNs were associated with a higher major adverse cardiac events rate than stent edges without a CN, whether treated or untreated.
Year:
2025
Background and Aims The large-scale, randomized ILUMIEN IV trial was examined to determine whether procedural guidance with optical coherence tomography (OCT) during percutaneous coronary intervention (PCI) of angiographically calcified lesions improves outcomes. Methods Patients with a single PCI target lesion were included in the present analysis. The presence of none, mild, moderate or severe lesion calcification was determined by an angiographic core laboratory. The primary imaging endpoint was the post-PCI minimal stent area (MSA) assessed by OCT. The primary clinical endpoint was 2-year target-vessel failure (TVF), a composite of cardiac death, target-vessel myocardial infarction (TV-MI), or ischaemia-driven target-vessel revascularization. Results In the overall population (n = 2114), there was a significant interaction between the effect of randomization to OCT guidance vs angiography guidance in lesions with moderate/severe calcification (n = 1082) vs no/mild calcification (n = 1032) on the 2-year rate of TVF (Pinteraction = .01). The post-PCI MSA in moderately and severely calcified lesions was larger with OCT guidance (n = 544) compared with angiography guidance (n = 538) (5.57 ± 1.86 mm2 vs 5.33 ± 1.78 mm2; P = .03). In the moderate/severe calcified lesion cohort, TVF within 2 years occurred in 35 patients with OCT guidance and in 51 patients with angiography guidance (6.8% vs 9.7%; adjusted hazard ratio [aHR] 0.62; 95% confidence interval [CI] 0.40–0.96), whereas there was no significant difference in TVF in the no/mild calcified lesion cohort (7.7% vs 5.2%; aHR 1.48; 95% CI 0.90–2.44) (Pinteraction = .01). In moderately/severely calcified lesions, OCT-guided PCI also reduced the 2-year rates of serious major adverse cardiac events (2.8% vs 4.7%; aHR 0.49; 95% CI 0.25–0.95; P = .03), TV-MI (1.9% vs 4.0%; aHR 0.36; 95% CI 0.17–0.79; P = .01), and stent thrombosis (0.2% vs 1.5%; aHR 0.11; 95% CI 0.01–0.89; P = .04) compared with angiography-guided PCI. Conclusions In the ILUMIEN IV trial, OCT-guided PCI in patients with angiographically determined moderately or severely calcified lesions reduced the 2-year rate of TVF compared with angiography-guided PCI, an effect that was not seen in patients with lesions with no or mild angiographic calcium.
Year:
2025
BACKGROUND: Bioresorbable scaffolds (BRS) were developed to overcome limitations related to late stent failures of drug-eluting stents, but lumen reductions over time after implantation of BRS have been reported. This study aimed to investigate if lesion preparation with a scoring balloon compared with a standard noncompliant balloon minimizes lumen reduction after implantation of a Magmaris BRS assessed with optical coherence tomography and intravascular ultrasound. METHODS: Eighty-two patients with stable angina were randomized in a ratio of 1:1 to lesion preparation with a scoring balloon versus a standard noncompliant balloon before implantation of a Magmaris BRS. The primary end point was minimal lumen area at 6-month follow-up. RESULTS: Following Magmaris BRS implantation, minimal lumen area (6.4±1.6 versus 6.3±1.5 mm 2 ; P =0.65), mean scaffold area (7.8±1.5 versus 7.5±1.7 mm 2 ; P =0.37), and mean lumen area (8.0±1.6 versus 7.7±2.1 mm 2 ; P =0.41) did not differ significantly in patients with lesions prepared with scoring versus standard noncompliant balloon, respectively. Six-month angiographic follow-up with optical coherence tomography and intravascular ultrasound was available in 74 patients. The primary end point, 6-month minimal lumen area, was significantly larger in lesions prepared with a scoring balloon compared with a standard noncompliant balloon (4.7±1.4 versus 3.9±1.9 mm 2 ; P =0.04), whereas mean lumen area (7.2±1.4 versus 6.8±2.2 mm 2 ; P =0.35) did not differ significantly. Intravascular ultrasound findings showed no difference in mean vessel area at the lesion site from baseline to follow-up in the scoring balloon group (16.8±2.9 versus 17.0±3.6 mm 2 ; P =0.62), whereas mean vessel area (17.1±4.4 versus 15.7±4.9 mm 2 ; P <0.001) was smaller in lesions prepared with a standard noncompliant balloon due to negative remodeling. CONCLUSIONS: Lesion preparation with a scoring balloon before implantation of a Magmaris BRS resulted in a significantly larger minimal lumen area after 6 months due to less negative remodeling compared with lesion preparation with a standard noncompliant balloon. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04666584.
Year:
2025
Background and Aims Observational registries have suggested that optical coherence tomography (OCT) imaging-derived parameters may predict adverse events after drug-eluting stent (DES) implantation. The present analysis sought to determine the OCT predictors of clinical outcomes from the large-scale ILUMIEN IV trial. Methods ILUMIEN IV was a prospective, single-blind trial of 2487 patients with diabetes or high-risk lesions randomized to OCT-guided versus angiography-guided DES implantation. All patients underwent final OCT imaging (blinded in the angiography-guided arm). From more than 20 candidates, the independent OCT predictors of 2-year target lesion failure (TLF; the primary endpoint), cardiac death or target-vessel myocardial infarction (TV-MI), ischaemia-driven target lesion revascularization (ID-TLR), and stent thrombosis were analysed by multivariable Cox proportional hazard regression in single treated lesions. Results A total of 2128 patients had a single treated lesion with core laboratory-analysed final OCT. The 2-year Kaplan–Meier rates of TLF, cardiac death or TV-MI, ID-TLR, and stent thrombosis were 6.3% (n = 130), 3.3% (n = 68), 4.3% (n = 87), and 0.9% (n = 18), respectively. The independent predictors of 2-year TLF were a smaller minimal stent area (per 1 mm2 increase: hazard ratio 0.76, 95% confidence interval 0.68–0.89, P < .0001) and proximal edge dissection (hazard ratio 1.77, 95% confidence interval 1.20–2.62, P = .004). The independent predictors of cardiac death or TV-MI were smaller minimal stent area and longer stent length; of ID-TLR were smaller intra-stent flow area and proximal edge dissection; and of stent thrombosis was smaller minimal stent expansion. Conclusions In the ILUMIEN IV trial, the most important OCT-derived post-DES predictors of both safety and effectiveness outcomes were parameters related to stent area, expansion and flow, proximal edge dissection, and stent length.
Year:
2024
Introduction Bioresorbable scaffolds (BRS) have been developed to overcome limitations related to late stent failures of drug-eluting-stents, but previous studies have observed lumen reduction over time after implantation of BRS. The aim of the study was to investigate if lesion preparation with a scoring balloon compared to a standard non-compliant balloon minimizes lumen reduction after implantation of a Magmaris BRS (MgBRS) assessed with optical coherence tomography (OCT) and intravascular ultrasound (IVUS). Method Eighty-two patients with stable angina pectoris were included and randomized in a ratio 1:1 to lesion preparation with either a scoring balloon or a standard non-compliant balloon prior to implantation of a MgBRS. The primary endpoint was minimal lumen area (MLA) 6 months after MgBRS implantation. Results Following MgBRS implantation, MLA (6.4 ± 1.6 mm 2 vs. 6.3 ± 1.5 mm 2 , p=0.65), mean scaffold area (7.8 ± 1.5 mm 2 vs. 7.5 ± 1.7 mm 2 , p=0.37), and mean lumen area (8.0 ± 1.6 mm 2 vs. 7.7 ± 2.1 mm 2 , p=0.41) did not differ significantly in patients where the lesions were prepared with scoring vs. standard non-compliant balloon respectively. Six-month angiographic follow-up with OCT and IVUS was available in seventy-four patients. The primary endpoint, 6-months MLA, was significantly larger in lesions prepared with a scoring balloon compared to a standard non-compliant balloon (4.7 ± 1.4 mm 2 vs. 3.9 ± 1.9 mm 2 , p=0.04), whereas mean lumen area (7.2 ± 1.4 mm 3 vs. 6.8 ± 2.2, p=0.35) did not differ significantly. IVUS findings showed no difference in mean vessel area at the lesion site from baseline to follow-up in the scoring balloon group (16.8 ± 2.9 mm 2 vs. 17.0 ± 3.6 mm 2 , p=0.62), whereas mean vessel area (17.1 ± 4.4 mm 2 vs. 15.7 ± 4.9 mm 2 , p<0.001) was smaller in lesions prepared with a standard non-compliant balloon due to negative remodeling. Conclusion Lesion preparation with a scoring balloon prior to implantation of a MgBRS resulted in significantly larger MLA after 6 months due to less negative remodeling compared to lesion preparation with a standard non-compliant balloon. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04666584 . Clinical perspectives What is new? - Intense lesion preparation with a scoring balloon prior to implantation of a magnesium-based Magmaris bioresorbable scaffold results in less lumen reduction and malapposition after 6 month compared to conventional lesion preparation with a non-compliant balloon in patients with stable angina. - Negative remodeling was seen in lesions treated with conventional lesion preparation, whereas optimal lesion preparation with a scoring balloon caused in stable remodeling. What are the Clinical Implications? - Lesions preparation with a scoring balloon is safe and ensures better vascular healing and vessel dynamics after implantation of a magnesium-based Magmaris bioresorbable scaffold. - Optimal lesion preparation should be considered before implantation of magnesium-based Magmaris bioresorbable scaffold.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Collaborators (12)
Rohit M. Oemrawsingh
Interventional Cardiologist, Head of Interventional Cardiology Research
-
Dalin Tang
Professor
Worcester Polytechnic Institute
William Wijns
Research Professor
National University of Ireland Galway
Gregg W. Stone
Icahn School of Medicine at Mount Sinai
Lisette Okkels Jensen
Professor
Odense University Hospital
James Spratt
Professor in Interventional Cardiology
St George’s, University of London
Patrick W. Serruys
Professor of Interventional Medicine and Innovation
University of Galway
Stuart Pocock
Professor of Medical Statistics
London School of Hygiene & Tropical Medicine
Björn Redfors
University of Gothenburg
Ori Ben-Yehuda
Professor
University of California, San Diego
Fernando Alfonso
Universidad Autónoma de Madrid
Arie Pieter Kappetein
Prof. Dr
Erasmus MC
Make your next move.
Prepare your application
Review drafts before you send them.